Ceramide Face Cream for Eczema: A 107-Child Trial Tested a Complete Formula, Not One Ingredient
Image: AI-created illustration of a fictional adult with facial dryness. It is not a child, a study participant or a result from Dr. Arsy #003. The research below tested a different manufacturer’s formulation.
A face cream’s ingredient headline can sound like a clinical result: “ceramides for eczema.” A formulation trial asks a narrower question. It compares particular finished products in a defined group, and cannot isolate which ingredient caused any difference. One childhood facial-eczema study makes that distinction especially useful.
What the facial study compared
The 2014 primary full report describes an assessor-blinded, randomized, six-week comparison involving 107 children with mild-to-moderate chronic facial atopic eczema. The methods and baseline table allocate 72 to Nutratopic Pro-AMP cream and 35 to a control cream.
The study formulation contained 2.5% rhamnosoft, ceramide 3 and 2% L-isoleucine. The comparison was a different finished moisturizing cream described as containing 15% glycerol, 8% petrolatum and 2% liquid paraffin. Both products were applied twice daily. This was not a test of adding ceramide alone to an otherwise identical vehicle, and it was not a comparison with Dr. Arsy #003.
The reported six-week results favored the study formula
| Reported measure | Pro-AMP formula | Control cream |
|---|---|---|
| Mean baseline facial Eczema Severity Score | 6.1 | 5.3 |
| Mean facial score at week six | 1.0 | 2.6 |
| Reported clear/almost-clear investigator assessment at week six | 88% | 58% |
The investigator assessed facial redness, thickening, scratching and lichenification. Lower mean scores indicate less measured disease activity. A lower score and a clear/almost-clear assessment are different outcomes; neither establishes permanent cure. Improvement in the control group also matters when judging the added value of the tested formulation.
The published report contains inconsistencies worth preserving
The methods specify ages six months to 14 years, but the results prose prints a range of six months to two years while also giving a mean age of six. The methods and table list 72 in the study-formula arm; a results sentence says 70. The abstract reports the week-six between-group score comparison as p=0.001, while the results prose gives p=0.0001. The intermediate control assessment is also described as week two in the abstract and week three in the main text.
These discrepancies should not be silently repaired or converted into a more precise claim than the report supports. The table above follows the methods, baseline table and reported score means while flagging the inconsistent prose. The experiment offers a formulation-specific signal with reporting limitations, rather than a clean basis for a universal percentage claim.
The paper calls the study nonprofit, but also discloses that an author employed by Isdin participated in design and manuscript preparation and that Isdin supplied the products. That relationship belongs beside the result. Blinding the assessor also does not mean the study was fully double-blind for families and all other personnel.
What the trial cannot tell a face-cream shopper
It cannot establish that all ceramide creams are interchangeable, that petrolatum is ineffective, or that an unrelated moisturizer will reproduce an 88% response. The products differ in several ingredients and the study did not isolate individual mechanisms. Short-term tolerability in this selected sample cannot establish universal pediatric suitability.
Our prescription-versus-OTC barrier-product trial guide addresses a separate comparison. The BEEP prevention study asked whether routine early moisturization prevented eczema; prevention in initially unaffected infants is not the same endpoint as treating existing facial disease.
Choose the question before the product claim
For a child with facial eczema, ask the clinician whether the immediate goal is treating inflammation, supporting dry skin or investigating a reaction to an ingredient. The pimecrolimus facial trials concern a prescription medicine in defined groups. The crisaborole healthy-skin study discussion shows why tolerability and disease efficacy also need separate evidence.
Dr. Arsy Moisturizer #003, 4 oz offers cosmetic hydration, moisture-barrier support and ordinary dry-skin comfort. It was not tested in this study and does not inherit another product’s ingredients, eczema-treatment results or pediatric-safety evidence. Ask the clinician which products are suitable for the child and facial area.
Educational information for adult caregivers; original full report checked November 9, 2026. No independent clinical review is claimed.